A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1 Safety Lead-In: Incidence of dose limiting toxicities

  Measured over: First 42 days after first elranatamab dose

• Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria

  Measured over: From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months

• Part 3: Frequency of treatment-emergent adverse events

  Measured over: First 84 days after first elranatamab dose

Changes Tremor has spotted